Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

Cluster Headache Clinical Trial

— BASIC  

Official title:

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03944876
• Other study ID #: 2018/1821
• Secondary ID: 2018-003148-21
• Status: Recruiting
• Phase: Phase 3
• Start date: November 1, 2019
• Est. completion date: September 2025

Study information

• Verified date: September 2023
• Source: Norwegian University of Science and Technology
• Contact: Tore Wergeland Meisingset, md phd
• Phone: +47 728 21 335
• Email: tore.w.meisingset[@]ntnu.no
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cluster headache is a primary headache condition characterized by clusters of one-sided, high-intensity pain attacks. The headache may be episodic or chronic. Treatment options are limited and their effects unsatisfactory. An important nerve pathway involved in the pain attacks has a switching station at the sphenopalatine ganglion (SPG) located in the depth of the facial bones. SPG is a known therapy target for cluster headache. The area can be identified on CT images, but is difficult to access due to its location. Thus, the Multiguide navigation system has been developed to enable precise delivery of the drugs that target SPG activity. In Trondheim, two phase 1 / Phase 2 study have been carried out using botulinum toxin A (Botox®) against SPG in patient with chronic cluster headache and chronic migraine. The results indicate that such a treatment strategy is safe and beneficial. The current study is a randomized, placebo-controlled, triple-blinded study to investigate whether precise single-injection of botulinum toxin A reduces the frequency of attacks in chronic cluster headache .

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 112
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Informed and written consent.

2. Male or female, 18-85 years of age

3. Headache attacks fulfilling the International Classification of Headache Disorders (ICHD) III criteria for chronic cluster headache (CCH) 3.1.2.

4. Dominant headache laterality with = 80% of cluster headache attacks on one side.

5. Subject reports an average of = 4 cluster attacks/week on the side of their dominant headache laterality in the 3 months prior to inclusion and in the baseline period.

6. The condition is pharmacologically refractory defined as suboptimal effect or intolerable side effects or contraindication for verapamil or lithium or suboccipital steroid injection.

7. Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during the whole study period.

8. Subject is able to differentiate concomitant headaches from cluster headache.

9. In case of women of childbearing potential (WOCBP) they have to be using highly effective contraception in a period of 4 weeks after injection.

10. Ability to understand study procedures and to comply with them for the entire length of the study

Exclusion Criteria:

1. Subject has had a change in type, dosage or dose frequency of preventive headache medications = two weeks prior to baseline/screening or 5 half-lives, whichever is longer.

2. Subject currently treated with occipital nerve stimulation, deep brain stimulation or other implantable device, that have changed parameters in the last month, or are unable to keep parameters stable throughout the study.

3. Current or previous treatment with implanted medical devices targeting the SPG

4. Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period, eg. prior to IMP administration.

5. Non-responder to both oxygen and triptan.

6. Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months before study drug administration or 5 half-lives, whichever is longer.

7. Subject is currently participating or has participated in the last 3 months in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.

8. Allergy or hypersensitivity reactions to marcaine, lidocaine, xylocaine, adrenaline, any botulinum toxin or similar substances.

9. Abuse of drugs or alcohol.

10. Use of opioids for =10 days per month.

11. Treatment with pharmacological substances that may interact with BTA (aminoglycosids, spectinomycin, neuromuscular blockers, both depolarizing agents (such as succinylcholine) or non-depolarizing (tubocurarine derivates), lincosamides, polymyxins, quinidine, magnesium sulfate or anticholinestases.).

12. WOCBP that do not adhere to the requirements for HEC, as noted in inclusion criteria 9 and outlined in section 3.3.

13. Pregnancy or breastfeeding in the study period

14. Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned injection site that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.

15. Facial anomaly or trauma which renders the procedure difficult.2

16. Subject currently has an active oral or dental abscess or a local infection at the site of injection based on present symptoms.

17. Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past 6 months.

18. Patients exhibiting a high degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.

19. Patients with comorbid psychiatric disorders with psychotic or other symptoms making compliance with the study protocol difficult, at the discretion of the investigator.

20. Patient with active infectious disease or infections that warrants special infection control measures, such as human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection.

21. Patient with disorders that are known contraindication for Botox® treatment, especially neuromuscular disorders such as motorneuron disorders and myasthenic syndromes

22. Subject has had previous radiofrequency ablation, balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the ipsilateral trigeminal ganglion or any branch of the trigeminal nerve.

23. Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the ipsilateral SPG.

24. Subject has had blocks of short-acting anaesthetics of the ipsilateral SPG in the last 3 months.

25. Subject has undergone onabotulinumtoxinA injections of the head and/or neck in the last 3 months.

26. Subject is anticipated to require any excluded medication, device, or procedure during the study.

27. Subject has a history of bleeding disorders and in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.

28. Subject has a history of coagulopathy.

29. Subject is unable to stop antithrombotic medication, eg. anticoagulants and/or antiplatelet therapy, before procedure.

30. The subject has been diagnosed with another trigeminal autonomic cephalalgia or trigeminal neuralgia.

31. The patient cannot participate or successfully complete the study, in the opinion of

their healthcare provider or the investigator, for any of the following reasons:

• mentally or legally incapacitated or unable to give consent for any reason.
• in custody due to an administrative or a legal decision, under tutelage, or being admitted to a sanatorium or social institution.

32. The patient is a study centre employee who is directly involved in the study or the relative of such an employee.

Related Conditions & MeSH terms

• Cluster Headache
• Ganglion Cysts
• Headache

Intervention

Drug:
• Botulinum toxin type A
Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
• placebo
0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)

Locations

Country	Name	City	State
Germany	Universitätsklinikum Hamburg Eppendorf	Hamburg
Italy	Fondazione IRCCS Istituto Neurologico Carlo Besta (CBNI)	Milano
Norway	St Olavs Hospital	Trondheim
Spain	Department of Neurology, University Clinic Hospital. Catholic University of Valencia	Valencia
United Kingdom	National Hospital of Neurology and Neurosurgery, University College of London	London

Sponsors (6)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology	Catholic University of Valencia, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, St. Olavs Hospital, Universitätsklinikum Hamburg-Eppendorf, University College, London

Countries where clinical trial is conducted

Germany,  Italy,  Norway,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in change from baseline week 5-8 in mean number of cluster headache attacks per week at weeks 5-8 post-intervention in the treatment group versus the placebo group	Change from baseline to weeks 5-8 post-intervention in number of cluster headache attacks per week in the active group versus the placebo group. The number of cluster headache attacks is collected in a headache diary.	week 5 through week 8 in the post-injection period
Secondary	Difference in occurrence of adverse events (AEs) and serious adverse events (SAEs) in the active group versus the placebo group	All adverse events and serious adverse events occurring in the 3 months follow up are registered in an electronic case report form (CRF). Frequency of AE and SAE are compared between the placebo group and the treatment group	week 1 through week 12 in the post-injection period
Secondary	Difference in change from baseline week 5-8 in mean number of cluster headache attacks per week during weeks 9-12 post-intervention in the active group versus the placebo group	Change from baseline to weeks 9-12 post-intervention in number of cluster headache attacks per week in the active group versus the placebo group. The number of cluster headache attacks is collected in a headache diary	week 9 through week 12 in the post-injection period
Secondary	Difference in change from baseline week 5-8 in mean number of cluster headache attacks per week at weeks 5-8 post-intervention in the active group versus the placebo group, in the prespecified subgroups	Change from baseline to weeks 5 - 8 post-intervention in number of cluster headache attacks per week comparing high versus low attack frequency and low versus high attack frequency variation in the entire baseline period. Comparisons are done between the active and the placebo group. The number of cluster headache attacks is collected in a headache diary	week 5 through week 8 in the post-injection period
Secondary	Difference in change from baseline week 5-8 in mean number of cluster headache attacks per week during weeks 9-12 post-intervention in the active group versus the placebo group, in the prespecified subgroups	Change from baseline to weeks 9-12 post-intervention in number of cluster headache attacks per week comparing high versus low attack frequency and high versus low attack frequency variation in the entire baseline period. Comparisons are done between the active and the placebo group. The number of cluster headache attacks is collected in a headache diary	week 9 through week 12 in the post-injection period
Secondary	Difference in the number of therapeutic responders in the active group versus the placebo group.	Number of therapeutic responders as defined as a = 30% reduction in attack frequency, intensity or both during weeks 5 - 8 post-intervention compared to baseline week 5-8. The number in the placebo and intervention group are compared	week 5 through week 8 in the post-injection period
Secondary	Difference in the number of attack frequency responders	Number of attack frequency responders as defined as a = 30% reduction in attack frequency during weeks 5-8 post-intervention compared to baseline. The number in the placebo and intervention group are compared	week 5 through week 8 in the post-injection period
Secondary	Difference in change from baseline week 5-8 in mean attack intensity week 5 - 8 post-intervention in the active group versus the placebo group.	Mean attack intensity (10-point numerical response scale - NRS) week 5-8 post intervention compared to baseline in the intervention group versus the placebo group.	week 5 through week 8 in the post-injection period